Literature DB >> 30589969

Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.

Fabio Salvatore Macaluso1, Maria Cappello2, Enrica Giuffrida2, Walter Fries3, Andrea Centritto3, Antonio Carlo Privitera4, Gaetano Inserra5, Roberto Vassallo6, Antonio Magnano7, Elisa Vinci7, Serena Garufi8, Marco Ventimiglia1, Sara Renna1, Rosalba Orlando1, Giulia Rizzuto1, Mario Cottone1, Ambrogio Orlando1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30589969     DOI： 10.1111/apt.15071

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  2 in total

Review 1.  Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.

Authors:  Sang Hyoung Park; Jae Cheol Park; Milan Lukas; Martin Kolar; Edward V Loftus
Journal:  Intest Res       Date:  2020-01-30

2.  Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.

Authors:  Sarah Fischer; Sarah Cohnen; Entcho Klenske; Heike Schmitt; Francesco Vitali; Simon Hirschmann; Andreas Ramming; Sebastian Zundler; Timo Rath; Sabine Krebs; Frank Dörje; Wolfgang Uter; Daniel Nagore; Sebastian Meyer; Markus F Neurath; Raja Atreya
Journal:  Therap Adv Gastroenterol       Date:  2021-01-14       Impact factor: 4.409
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.